Page last updated: 2024-11-13

pituitary adenylate cyclase activating polypeptide 38

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID44566111
MeSH IDM0456497

Synonyms (15)

Synonym
pituitary adenylate cyclase-activating peptide-38
peptide pacap 38
pacap 38 ,
128606-20-2
human pacap-(1-38)
unii-lk78t72mlt
lk78t72mlt ,
human pacap-38
pituitary adenylate cyclase-activating peptide-38 (sheep)
124123-15-5
pacap 38 (human)
pacap 38 (sheep)
ovine pacap (1-38)
pituitary adenylate cyclase-activating peptide-38 (human)
DTXSID50154224
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vasoactive intestinal polypeptide receptor 1Homo sapiens (human)IC50 (µMol)0.00000.00000.00000.0000AID1336346; AID752225
Pituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)IC50 (µMol)0.00310.00020.00310.0061AID346444; AID350582
Pituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)Ki0.00020.00020.00020.0002AID346444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)EC50 (µMol)0.00210.00210.00210.0021AID350584
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathwayVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
positive regulation of cell population proliferationVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
spermatogenesisPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
response to xenobiotic stimulusPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
positive regulation of calcium ion transport into cytosolPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
cAMP-mediated signalingPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
cell differentiationPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
response to estradiolPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
multicellular organismal response to stressPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
positive regulation of cAMP-mediated signalingPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
response to ethanolPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
development of primary female sexual characteristicsPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
positive regulation of small GTPase mediated signal transductionPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
negative regulation of response to reactive oxygen speciesPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
vasoactive intestinal polypeptide receptor activityVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
protein bindingVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
peptide hormone bindingVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
vasoactive intestinal polypeptide receptor activityPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
protein bindingPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
adenylate cyclase bindingPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
small GTPase bindingPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
signaling receptor activityPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
neuropeptide bindingPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
peptide hormone bindingPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
G protein-coupled peptide receptor activityPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
receptor complexVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
plasma membraneVasoactive intestinal polypeptide receptor 1Homo sapiens (human)
endosomePituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
plasma membranePituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
caveolaPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
bicellular tight junctionPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
cell surfacePituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
intracellular membrane-bounded organellePituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
receptor complexPituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
plasma membranePituitary adenylate cyclase-activating polypeptide type I receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID346444Displacement of radiolabeled PACAP1-38 from human PACAP2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID1336346Displacement of [125I]PACAP1-27 from human recombinant PAC1 receptor expressed in CHO cells measured after 120 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID752225Binding affinity to human VPAC1 receptor by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID350585Agonist activity at human recombinant PAC1 receptor expressed in CHO cells assessed as PACAP38-induced calcium mobilization by FLIPR assay relative to PACAP382009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor.
AID350584Agonist activity at human recombinant PAC1 receptor expressed in CHO cells assessed as calcium mobilization by FLIPR assay2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor.
AID350582Displacement of [125I]Ac-PACAP27 from human recombinant PAC1 receptor expressed in CHO cells by gamma- counter2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor.
AID751862Binding affinity to human PACAP receptor by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]